Citadel Advisors’s 89bio ETNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-81,300
| Closed | -$1.2M | – | 13016 |
|
|
2025
Q3 | $1.2M | Buy |
81,300
+51,900
| +177% | +$529K | ﹤0.01% | 7154 |
|
|
2025
Q2 | $289K | Sell |
29,400
-14,100
| -32% | -$117K | ﹤0.01% | 9898 |
|
|
2025
Q1 | $316K | Buy |
43,500
+14,700
| +51% | +$129K | ﹤0.01% | 9466 |
|
|
2024
Q4 | $225K | Sell |
28,800
-5,300
| -16% | -$43.6K | ﹤0.01% | 10234 |
|
|
2024
Q3 | $252K | Buy |
34,100
+14,000
| +70% | +$118K | ﹤0.01% | 9653 |
|
|
2024
Q2 | $161K | Sell |
20,100
-67,300
| -77% | -$601K | ﹤0.01% | 10234 |
|
|
2024
Q1 | $1.02M | Sell |
87,400
-17,800
| -17% | -$197K | ﹤0.01% | 6884 |
|
|
2023
Q4 | $1.18M | Buy |
105,200
+53,000
| +102% | +$487K | ﹤0.01% | 6358 |
|
|
2023
Q3 | $806K | Buy |
52,200
+33,500
| +179% | +$562K | ﹤0.01% | 7019 |
|
|
2023
Q2 | $354K | Sell |
18,700
-62,900
| -77% | -$1.1M | ﹤0.01% | 8678 |
|
|
2023
Q1 | $1.24M | Buy |
81,600
+22,400
| +38% | +$292K | ﹤0.01% | 6317 |
|
|
2022
Q4 | $754K | Sell |
59,200
-29,400
| -33% | -$265K | ﹤0.01% | 7380 |
|
|
2022
Q3 | $513K | Buy |
88,600
+57,000
| +180% | +$250K | ﹤0.01% | 8398 |
|
|
2022
Q2 | $102K | Buy |
+31,600
| New | +$95.4K | ﹤0.01% | 11397 |
|
|
2021
Q2 | – | Sell |
-9,600
| Closed | -$227K | – | 13851 |
|
|
2021
Q1 | $227K | Buy |
+9,600
| New | +$222K | ﹤0.01% | 11461 |
|
Other funds holding ETNB
Citadel Advisors's ETNB Position: Q4 2025 in Review
Citadel Advisors sold out of 89bio (ETNB) in Q4 2025, closing a stake of 151,350 shares — an estimated $2.22M sold.
Citadel Advisors first reported a position in ETNB in Q3 2020 and held it in 21 quarters. The position peaked at $37.7M in Q2 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.
- Citadel Advisors reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 151,350 89bio shares in Q4 2025, an estimated $2.22M.
- Citadel Advisors first reported a position in 89bio in Q3 2020 and held it in 21 quarters.
- Citadel Advisors's 89bio position peaked at $37.7M in Q2 2025.
- 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.